Two or three doses of human papillomavirus vaccine? Switching to two doses looks feasible, but only with careful monitoring

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Brotherton, Julia ^a  

^a National HPV Vaccination Program Register   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; DOSAGE SCHEDULE COMPARISON; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; IMMUNITY; IMMUNOSTIMULATION; PAPILLOMAVIRUS INFECTION; QUALITY OF LIFE; VACCINATION; VIRUS LIKE AGENT; VIRUS LOAD; ECONOMICS; FEMALE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84921341074     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g7778     Document Type: Editorial

References (12)

1. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032.
2. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227.
3. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014;14:958-66.
4. Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:g1458.
5. Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013;32:26-32.
6. Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014;111:1824-30.
7. Hariri S, Markowitz LE, Dunne EF, Unger ER. Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 2013;53:679-82.
8. Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 2014;25:915-22.
9. Jit M, Brisson M, Laprise JF, Choi YH. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 2015;350:g7584.
10. Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis 2014; published online 24 Nov.
11. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014;89:465-91.
12. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. www.nice.org.uk/article/pmg9/chapter/Foreword.